SBIR Phase I:Magnetic Vectoring of Nanoparticle Drug-Carriers for Tumor-Specific Delivery of Chemotherapeutics

Award Information
Agency:
National Science Foundation
Branch
n/a
Amount:
$149,959.00
Award Year:
2010
Program:
SBIR
Phase:
Phase I
Contract:
1013705
Award Id:
99067
Agency Tracking Number:
1013705
Solicitation Year:
n/a
Solicitation Topic Code:
N4
Solicitation Number:
n/a
Small Business Information
124 N Bryant Ave, Suite C-3, Edmond, OK, 73034
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
076334205
Principal Investigator:
Charles Seeney
PhD
(405) 844-5118
seen111@nanobmi.com
Business Contact:
Charles Seeney
PhD
(405) 844-5118
seen111@nanobmi.com
Research Institution:
n/a
Abstract
This Small Business Innovation Research (SBIR) Phase I project aims to develop a tumor-specific delivery technology based on the use of superparamagnetic nanoparticles as vehicles for the delivery of paclitaxel. The magnetic vectoring drug delivery platform uses external shaped magnetic field gradients to concentrate nanoparticle-drug constructs at a target site, followed by tumor extravasation. This project will focus on the treatment of superficial tumors, such as locally advanced breast cancers (LABC). These tumors pose a difficult and, as yet, unresolved clinical problem as most patients presenting with this disease will experience resistance and pronounced toxicity for current therapeutics. Therefore, a significant need exists for advanced therapies that can improve patient outcomes. A key distinguishing feature of this technology is the potential to overcome tumor interstitial pressure that normally tends to thwart free drug penetration. The broader/commercial impact of this project will be the potential to provide localized delivery of therapeutics in a manner that improves both therapeutic and economic benefits to patients. The urgency for such advanced delivery methods is increasing as new classes of pharmaceuticals, such as siRNAs and stem cells, are being developed and brought to market. Because these new therapeutics are more effective through localized therapy, advanced delivery systems that support their full therapeutic potential must be developed. The capacity to magnetically vector therapeutics, tumor-specifically, will have a significant impact on both patient treatment strategies and outcomes.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government